Antares Pharma (NASDAQ: ATRS) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $6.43 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.